PCM
SUPN icon

Prelude Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Prelude Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-9,300
Closed -$308K – 2031
2019
Q2 		$308K Buy
9,300
+1,400
+18% +$48K 0.02% 610
2019
Q1 		$277K Buy
+7,900
New +$294K 0.02% 620
2018
Q4 		– Sell
-22,500
Closed -$1.13M – 2136
2018
Q3 		$1.13M Buy
+22,500
New +$1.11M 0.07% 345

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return

Prelude Capital Management's SUPN Position: Q4 2020 in Review

Prelude Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q4 2020, closing a stake of 1,046 shares — an estimated $22K sold.

Prelude Capital Management first reported a position in SUPN in Q4 2014 and held it in 18 quarters. The position peaked at $590K in Q2 2018. 225 funds tracked by Wall St. Rank hold SUPN as of Q4 2020.

  • Prelude Capital Management reported no remaining Supernus Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Prelude Capital Management sold 1,046 Supernus Pharmaceuticals shares in Q4 2020, an estimated $22K.
  • Prelude Capital Management first reported a position in Supernus Pharmaceuticals in Q4 2014 and held it in 18 quarters.
  • Prelude Capital Management's Supernus Pharmaceuticals position peaked at $590K in Q2 2018.
  • 225 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2020.

Based on Prelude Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.